HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coral LLC Looks To Rehabilitate Coral Calcium With Expanded Applications

This article was originally published in The Tan Sheet

Executive Summary

Coral LLC not only faces competition for consumer spending on dietary supplements, but also must overcome negative connotations associated with its coral calcium ingredient

You may also be interested in...

New Products In Brief

I AM opens doors, launches liquids

Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations

In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for

Lawyers Question FDA’s Broad Brush Approach In Cancer Claims Crackdown

Dietary supplement trade groups say FDA's recent crackdown on products with unsubstantiated cancer claims helps firms that use appropriate marketing, but food and drug lawyers say the agency may have applied too much of a broad brush approach

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts